Page 91 - Read Online
P. 91

Page 6 of 7           Fouad et al. Metab Target Organ Damage 2024;4:20  https://dx.doi.org/10.20517/mtod.2024.26

               Financial support and sponsorship
               None.


               Conflict of interest
               Amedeo Lonardo is the Editor-in-Chief of the journal Metabolism and Target Organ Damage. The other
               authors declare that there are no conflicts of interest.

               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2024.

               REFERENCES
               1.       Fouad Y, Dufour JF, Zheng MH, et al. The NAFLD-MAFLD debate: is there a consensus-on-consensus methodology? Liver Int
                   2022;42:742-8.  DOI
               2.       Fouad Y, Elwakil R, Elsahhar M, et al. The NAFLD-MAFLD debate: eminence vs evidence. Liver Int 2021;41:255-60.  DOI
               3.       Méndez-Sánchez N, Zheng MH, Kawaguchi T, Sarin SK. Editorial: the metabolic (dysfunction) associated fatty liver disease
                   (MAFLD)-non-alcoholic fatty liver disease (NAFLD) debate: a forced consensus and the risk of a world divide. Med Sci Monit
                   2022;28:e938080.  DOI  PubMed  PMC
               4.       Fouad YM, Gomaa A, El Etreby RM, AbdAllah M, Attia D. Editorial: the metabolic (dysfunction)-associated fatty liver disease
                   (MAFLD) and non-alcoholic fatty liver disease (NAFLD) debate: why the american association for the study of liver diseases
                   (AASLD) and European association for the study of the liver (EASL) consensus process is not representative. Med Sci Monit
                   2022;28:e938066.  DOI  PubMed  PMC
               5.       Malhi H, Brown RS Jr, Lim JK, et al. Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for
                   and expectations of AASLD journals. Liver Transpl 2023;29:1262-3.  DOI
               6.       Shiha G, Korenjak M, Eskridge W, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol
                   Hepatol 2021;6:73-9.  DOI
               7.       Sanal MG. Is the change from NAFLD to MASLD driven by political correctness? J Hepatol 2024;80:e74-6.  DOI  PubMed
               8.       Alboraie M, Fouad Y, Eslam M. Letter to the editor: MAFLD versus MASLD-which is more appropriate from a global perspective?
                   Hepatology 2024.  DOI
               9.       Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert
                   consensus statement. Lancet Gastroenterol Hepatol 2021;6:864-73.  DOI
               10.      Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international
                   expert consensus statement. J Hepatol 2020;73:202-9.  DOI
               11.      Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic
                   associated fatty liver disease. Gastroenterology 2020;158:1999-2014.e1.  DOI  PubMed
               12.      Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the
                   diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020;14:889-919.  DOI
               13.      Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat
                   Rev Gastroenterol Hepatol 2022;19:638-51.  DOI
               14.      Kurtulmuş F. The democratization of science. Global Epistemologies and Philosophies of Science. London: Routledge; 2021. pp. 145-
                   54.
               15.      Carolan MS. Science, expertise, and the democratization of the decision-making process. Soc Natur Resour 2006;19:661-8.  DOI
               16.      Méndez-Sánchez N, Bugianesi E, Gish RG, et al; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global
                   multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol 2022;7:388-90.  DOI  PubMed
               17.      Méndez-Sánchez N, Maris-Gil S, Alonso-Rivera CG. Latin American association of pediatrics (ALAPE) endorses the MAFLD
                   definition of fatty liver disease. J Hepatol 2022;77:249.  DOI
               18.      Nan Y, An J, Bao J, et al. The Chinese society of hepatology position statement on the redefinition of fatty liver disease. J Hepatol
                   2021;75:454-61.  DOI
               19.      Shiha G, Alswat K, Al Khatry M, et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the
                   Middle East and north Africa. Lancet Gastroenterol Hepatol 2021;6:57-64.  DOI
               20.      Spearman CW, Desalegn H, Ocama P, et al. The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From
                   NAFLD to MAFLD. J Hepatol 2021;74:1256-8.  DOI
               21.      Berlivet L, Löwy I. Hydroxychloroquine controversies: clinical trials, epistemology, and the democratization of science. Med
                   Anthropol Q 2020;34:525-41.  DOI  PubMed  PMC
   86   87   88   89   90   91   92   93   94   95   96